Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Simultaneous study of five candidate target antigens (CD20, CD22, CD33, CD52, HER2) for antibody-based immunotherapy in B-ALL: a monocentric study of 44 cases

Leukemia volume 23, pages 806–807 (2009)Cite this article

In the last few years, targeted immunotherapy for haematological diseases has been developed to reduce the toxicity of chemotherapy and to improve treatment efficacy.1 As the prognosis of B-acute lymphoblastic leukaemia (B-ALL) in adults and in some children remains poor, we have investigated the simultaneous expression of five target surface antigens (sAg) (CD20, CD22, CD33, CD52, HER2) for which monoclonal antibodies are currently available for immunotherapy (rituximab, epratuzumab, gemtuzumab, alemtuzumab, trastuzumab).

We have identified a series of 44 B-ALL (22 males and 22 females) at diagnosis (n=40) or at relapse (n=4) between March 2000 and June 2008. The median age was 51 (range 5–92) years. There were 13 Philadelphia positive B-ALL. CD20, CD22, CD33, CD52 and HER2 expression was assessed using multicolour flow cytometry with the following phycoerythrin-conjugated monoclonal antibodies directed against: CD20 (L27), CD22 (SHCL1), CD33 (P67.6), HER2 (Neu 24.7) purchased from BD (San Jose, CA, USA) and CD52 (CF1.D12) purchased from Caltag (Buckingham, UK). A CD19+CD45+low blast cell gating strategy was also used. The mean fluorescence intensity ratio was obtained by dividing the mean fluorescence intensity of the considered antibody by that of its isotypic control. Positivity threshold was defined by a ratio intensity of ⩾2.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Kuriakose P . Targeted therapy for hematologic malignancies. Cancer Control 2005; 12: 82–90.

    Article  PubMed  Google Scholar 

  2. Ferreri AJ, Dognini GP, Verona C, Patriarca C, Doglioni C, Ponzoni M . Re-occurrence of the CD20 molecule expression subsequent to CD20-negative relapse in diffuse large B-cell lymphoma. Haematologica 2007; 92: e1–e2.

    Article  CAS  PubMed  Google Scholar 

  3. Raetz EA, Cairo MS, Borowitz MJ, Blaney SM, Krailo MD, Leil TA et al. Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a children'soncology group pilot study. J Clin Oncol 2008; 26: 3756–3762.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Chevallier P, Mahe B, Garand R, Talmant P, Harousseau JL, Delaunay J . Combination of chemotherapy and gemtuzumab ozogamicin in adult Philadelphia positive acute lymphoblastic leukaemia patient harbouring CD33 expression. Int J Hematol 2008; l88: 209–211.

    Article  Google Scholar 

  5. Laporte JP, Isnard F, Garderet L, Fouillard L, Gorin NC . Remission of adult acute lymphocytic leukaemia with alemtuzumab. Leukemia 2004; 18: 1557–1558.

    Article  CAS  PubMed  Google Scholar 

  6. Chevallier P, Robillard N, Wuilleme-Toumi S, Mechinaud F, Harousseau JL, Avet-Loiseau H . Overexpression of Her2/neu is observed in one third of adult acute lymphoblastic leukaemia patients and is associated with chemoresistance in these patients. Haematologica 2004; 89: 1399–1401.

    PubMed  Google Scholar 

  7. Zent CS, Call TG, Shanafelt TD, Tschumper RC, Jelinek DF, Bowen DA et al. Early treatment of high-risk chronic lymphoblastic leukaemia with alemtuzumab and rituximab. Cancer 2008; 113: 2110–2118.

    Article  CAS  PubMed  Google Scholar 

  8. Chevallier P, Robillard N, Ayari S, Guillaume T, Delaunay J, Mechinaud F et al. Persistence of CD33 expression at relapse in CD33+ AML patients after receiving gemtuzumab in the course of the disease. Br J Haematol 2008, (in press) DOI:10.1111/j.1365-2141.2008-07153.x.

Download references

Author information

Authors and Affiliations

  1. Service d’Hématologie Clinique, CHU de Nantes, Nantes, France

    P Chevallier, S Ayari, T Guillaume, J Delaunay, J-L Harousseau & M Mohty

  2. Laboratoire d’Hématologie, CHU de Nantes, Nantes, France

    N Robillard, G Houille, H Avet-Loiseau & R Garand

Authors
  1. P Chevallier
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N Robillard
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G Houille
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S Ayari
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. T Guillaume
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J Delaunay
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J-L Harousseau
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. H Avet-Loiseau
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. M Mohty
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. R Garand
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P Chevallier.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chevallier, P., Robillard, N., Houille, G. et al. Simultaneous study of five candidate target antigens (CD20, CD22, CD33, CD52, HER2) for antibody-based immunotherapy in B-ALL: a monocentric study of 44 cases. Leukemia 23, 806–807 (2009). https://doi.org/10.1038/leu.2008.303

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2008.303

This article is cited by

Search

Advanced search

Quick links